1 November 2020 in Journal of the Neurological Sciences
21 April 2021 in European Journal of Neurology
Background and purpose: COVID‐19‐related acute neurological phenotypes are being increasingly recognised, with neurological complications reported in more than 30% of hospitalised patients. However, multicentric studies providing a population‐based perspective are lacking.Methods: We conducted a retrospective multicentric study at five hospitals in Northern Portugal, representing 45.1% of all hospitalised patients in this region, between 1 March and 30 June 2020.Results: Among 1261 hospitalised COVID‐19 patients, 457 (36.2%) presented neurological manifestations, corresponding to a rate of 357 per 1000 in the North Region. Patients with neurologic manifestations were younger (68.0 vs. 71.2 years, p = 0.002), and the most frequent neurological symptoms were headache (13.4%), delirium (10.1%), and impairment of consciousness (9.7%). Acute well‐defined central nervous system (CNS) involvement was found in 19.1% of patients, corresponding to a rate of 217 per 1000 hospitalised patients in the whole region. Assuming that all patients with severe neurological events were hospitalised, we extrapolated our results to all COVID‐19 patients in the region, estimating that 116 will have a severe neurological event, corresponding to a rate of nine per 1000 (95% CI = 7–11). Overall case fatality in patients presenting neurological manifestations was 19.8%, increasing to 32.6% among those with acute well‐defined CNS involvement.Conclusions: We characterised the population of hospitalised COVID‐19 patients in Northern Portugal and found that neurological symptoms are common and associated with a high degree of disability at discharge. CNS involvement with criteria for in‐hospital admission was observed in a significant proportion of patients. This knowledge provides the tools for adequate health planning and for improving COVID‐19 multidisciplinary patient care.
19 May 2025 in European Journal of Neurology
Background: Headache is a symptom of the long‐COVID syndrome. The incidence and characteristics of de novo post‐COVID headaches remain unclear. Our aim was to characterize new‐onset headaches in a population‐based prospective cohort of COVID‐19 patients from the first pandemic wave.Methods: This study followed a prospective cohort of 732 COVID‐19 patients consecutively diagnosed between March and June 2020. Neurological follow‐up was performed face‐to‐face or by phone at 3, 12, and 24 months. A structured clinical questionnaire was used to characterize headaches before infection and 24 months postinfection.Results: Overall, 448 patients completed the 24‐month follow‐up, with a mean age of 51.6 years at SARS‐CoV‐2 infection; 272 (60.7%) were women. A prior history of headaches was reported by 115 (25.7%). Patients with either pre‐existing or de novo persistent headaches were younger, more often women, and exhibited hyposmia, hypogeusia, and headache during the acute phase of infection. De novo persistent headaches occurred in 54 of 333 (16.2%) headache‐naïve patients. Of these, 35 (64.8%) fulfilled migraine‐like headache (MLH) criteria (mean age of 49.1 years at 24‐month follow‐up), with a cumulative incidence of 42/1000/year.Conclusions: De novo persistent headaches are common 2 years after COVID‐19, with MLH being the most frequent type. MLH incidence after COVID‐19 is elevated and de novo “migraineurs‐like” tend to be older compared to the general population. This is an important finding with potential implications for healthcare and quality of life, considering the high number of COVID‐19 cases and the global burden of migraine.
15 December 2022 in Movement Disorders Clinical Practice
3 March 2020 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
21 December 2020 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques